A protein produced by cells in response to stress can improve the production of biological medicines

February 11, 2016
A protein produced by cells in response to stress can improve the production of biological medicines
Photo at 200 times magnification of a culture of antibody producing CHO cells. Credit: A*STAR Bioprocessing Technology Institute

Production of an antibody can be doubled without loss in quality by genetically modifying special cells to overexpress heat shock protein 27 (HSP27), a Singaporean research team has shown, bringing efficient production of therapeutics a step closer.

Cultures of Chinese hamster ovary (CHO) are used to produce large quantities of biological medicines known as biologics. DNA is artificially constructed with specially chosen gene sequences and inserted into CHO cells. The 'recombinant DNA' instructs the cells to produce proteins that are then used for medical purposes.

Scientists from A*STAR's Bioprocessing Technology Institute (BTI) and the National University of Singapore have now genetically modified CHO cells to overexpress 27. Under typical conditions, CHO cells die in culture, due to build-up of waste by-products, which limits the amount of recombinant biologics they can produce.

By studying gene and protein expression in CHO BTI researchers previously found that HSP27 levels were low when the growth of CHO cells was slow. "We speculated that more HSP27 in the CHO cells could prolong the culture's life and accordingly increase the concentrations of the biologics they produce," says BTI bioprocess scientist Janice Tan Gek Ling.

To demonstrate the concept, the team overexpressed HSP27 in CHO cells engineered to produce an antibody that binds to an antigen, called Rh factor, which is commonly present on . This antibody can prevent Rh disease, where Rh incompatibility between a pregnant mother and her fetus can lead to a dangerous breakdown in the newborn baby's red blood cells—acute cases can kill the baby in utero.

Together with their previous study that used CHO cells engineered to produce recombinant human interferon gamma—a therapy for hereditary immune and bone diseases — the team has shown that use of overexpressed HSP27 can improve the production of different recombinant biologics.

"Companies developing new biologic products can choose to implement this technology by using a host cell line designed to overexpress HSP27," says BTI Staff Scientist Ng Say Kong. In future, rather than having to engineer the cell lines from scratch, there could be new additives to add to CHO cultures which would simplify using this technology in existing manufacturing plants.

The team is now pursuing a more in-depth understanding of how HSP27 works. "With this knowledge, we can further engineer the CHO cell cultures to have an even longer culture life and higher cell growth leading to higher production of biologics," says Ng.

Explore further: Accelerating cellular assembly lines

More information: Janice G.L. Tan et al. Heat shock protein 27 overexpression in CHO cells modulates apoptosis pathways and delays activation of caspases to improve recombinant monoclonal antibody titre in fed-batch bioreactors, Biotechnology Journal (2015). DOI: 10.1002/biot.201400764

Related Stories

Accelerating cellular assembly lines

January 2, 2013

The immune system generates antibodies to mark threats that need to be eliminated, and these protein complexes bind their targets with remarkable strength and selectivity. Scientists have learned how to generate cell lines ...

Recommended for you

Ten months in the air without landing

October 27, 2016

Common swifts are known for their impressive aerial abilities, capturing food and nest material while in flight. Now, by attaching data loggers to the birds, researchers reporting in the Cell Press journal Current Biology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.